Department of Pediatrics, Mehta Multispeciality Hospitals India Pvt Ltd, India.
Department of Pediatric Endocrinology, Mehta Multispeciality Hospitals India Pvt Ltd, India.
Pediatr Endocrinol Diabetes Metab. 2021;27(1):19-25. doi: 10.5114/pedm.2020.101807.
To assess the response of South Indian children with growth hormone deficiency (GHD) to growth hormone therapy, optimal duration of therapy for good catch up, and factors determining the response of our children to growth hormone therapy.
We conducted a case control study at a paediatric endocrine unit of a tertiary paediatric hospital. Children diagnosed with growth hormone deficiency were initiated on GH (cases) or followed up without GH therapy (controls). Detailed clinical, biochemical, radiological, and treatment parameters were recorded at baseline and follow-up. Data were analysed using IBM SPSS version 21.
We enrolled 23 subjects in group I (cases who received GH) and group II (controls with untreated children), and both the groups were comparable at baseline. Group I (-4.12 ±1.7 to -2.81 ±1.52) had significant height increase on follow-up after GH therapy compared to group II (-3.55 ±1.7 to -3.51 ±1.52) (p > 0.05). Growth velocity in group I (13.25 ±5.6 cm/year, SD score 4.55 ±5.42) was significantly higher compared to group II (3.4 ±1.8 cm/year, SD score -1.62 ±2.38). Duration of growth hormone therapy, presence of ectopic posterior pituitary, and BA: CA ratio independently impacted the growth velocity SD scores. Kaplan Meier analysis curve showed 15 months of GH therapy was needed to attain a height within ±2 SD of the target height.
Early diagnosis, pre-pubertal status, delayed bone age, and presence of ectopic posterior pituitary on MRI are determinants of a better response. Growth hormone must be administered for at least 15 months for catch up height SDs within target height SD range.
为了评估印度南部儿童生长激素缺乏症(GHD)对生长激素治疗的反应,确定治疗达到良好追赶生长的最佳持续时间,以及确定我们的孩子对生长激素治疗反应的因素。
我们在一家三级儿科医院的儿科内分泌科进行了一项病例对照研究。将被诊断为生长激素缺乏症的儿童开始接受 GH 治疗(病例组)或不接受 GH 治疗(对照组)进行随访。在基线和随访时记录详细的临床、生化、放射学和治疗参数。使用 IBM SPSS 版本 21 分析数据。
我们招募了 23 名 I 组(接受 GH 治疗的病例组)和 II 组(未接受 GH 治疗的对照组)的受试者,两组在基线时具有可比性。与 II 组(-3.55 ±1.7 至-3.51 ±1.52)相比,I 组(-4.12 ±1.7 至-2.81 ±1.52)在接受 GH 治疗后的随访中身高显著增加(p > 0.05)。I 组的生长速度(13.25 ±5.6 cm/年,SD 评分 4.55 ±5.42)明显高于 II 组(3.4 ±1.8 cm/年,SD 评分-1.62 ±2.38)。生长激素治疗持续时间、异位后垂体的存在以及 BA:CA 比值独立影响生长速度 SD 评分。Kaplan-Meier 分析曲线表明,需要 15 个月的 GH 治疗才能达到目标身高的±2 SD 范围内的身高。
早期诊断、青春期前状态、延迟骨龄和 MRI 上异位后垂体的存在是更好反应的决定因素。为了使追赶生长的 SD 达到目标身高的 SD 范围内,必须至少给予 15 个月的生长激素治疗。